Stay updated with breaking news from Jun Yoon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
12-week Phase 2a and Phase 1b multiple ascending dose topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and... | June 11, 2023
Structure Therapeutics announced that the Company will present three scientific posters at the upcoming 2023 American Thoracic Society (ATS) International Conference.
11.05.2023 - Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half 2023 SAN FRANCISCO and SHANGHAI, May 11, 2023 ...
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public offering SAN FRANCISCO and SHANGHAI, March 30, 2023 ...
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public offering SAN FRANCISCO and SHANGHAI, March 30, 2023 (GLOBE...